ALK-Rearranged Non-Small Cell Lung Cancer Presenting as a Large Mediastinal Mass: A Case Report

被引：0
|
作者：
Weber, Urs M. [1 ]
Einhorn, Lawrence [2 ]
Bunn, Paul A. [1 ]
机构：
[1] Univ Colorado, Div Med Oncol, Anschutz Med Campus, Aurora, CO 80309 USA
[2] Indiana Univ Sch Med, Div Hematol Oncol, Indianapolis, IN USA
来源：
JCO PRECISION ONCOLOGY | 2025年 / 9卷
关键词：
D O I：
10.1200/PO-24-00536
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Targeting ALK-rearranged non-small-cell lung cancer: an update
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2017, 13 (14) : 1213 - 1217
  • [32] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1474 - 1474
  • [33] Adaptive resistance to lorlatinib by EGFR activation in ALK-rearranged non-small cell lung cancer cells
    Katayama, Yuki
    Tanimura, Keiko
    Morimoto, Kenji
    Horinaka, Mano
    Sakai, Toshiyuki
    Ozasa, Hiroaki
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 830 - 830
  • [34] Treatment Sequences in ALK-rearranged Non-small Cell Lung Cancer; What Happens in the Real World?
    Chazan, G.
    Franchini, F.
    Shah, R.
    Alexander, M.
    John, A.
    IJzerman, M.
    Solomon, B.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S428 - S428
  • [35] Crizotinib for ALK-Rearranged Non-Small Cell Lung Cancer: A New Targeted Therapy for a New Target
    Gandhi, Leena
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2012, 18 (14) : 3737 - 3742
  • [36] Erratum to: Alectinib: A Review of Its Use in Advanced ALK-Rearranged Non-Small Cell Lung Cancer
    Kate McKeage
    Drugs, 2015, 75 : 241 - 241
  • [37] Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
    Califano, Raffaele
    Greystoke, Alastair
    Lal, Rohit
    Thompson, Joyce
    Popat, Sanjay
    LUNG CANCER, 2017, 111 : 51 - 58
  • [38] ALK-rearranged non-small cell lung cancer: how to optimize treatment with crizotinib in routine practice?
    Audigier-Vaiette, Clarisse
    Girard, Nicolas
    Cortot, Alexis B.
    Mennecier, Bertrand
    Debieuvre, Didier
    Planchard, David
    Zalcman, Gerard
    Moro-Sibilot, Denis
    Cadranel, Jacques
    Barlesi, Fabrice
    BULLETIN DU CANCER, 2014, 101 (09) : 823 - 831
  • [39] THE USE EXPERIENCE OF CRIZOTINIB (XALKORI®) FOR POSTOPERATIVE RECURRENCE OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER
    Noma, Daisuke
    Sakamoto, Kazuhiro
    Ando, Kohei
    Amano, Shinya G.
    Sudo, Shigeto
    Goto, Hideto
    Yamakawa, Yasushi
    Tsubakihara, Motofumi
    Tsuboi, Masahiro
    Masuda, Munetaka
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1320 - S1320
  • [40] Treatment patterns and outcomes in early-stage ALK-rearranged non-small cell lung cancer
    Schmid, Sabine
    Garcia, Miguel
    Cheng, Sierra
    Zhan, Luna
    Chotai, Simren
    Balaratnam, Karmugi
    Khan, Khaleeq
    Patel, Devalben
    Brown, M. Catherine
    Sachdeva, Robin
    Xu, Wei
    Shepherd, Frances A.
    Sacher, Adrian
    Leighl, Natasha B.
    Bradbury, Penelope
    Moriarty, Patrick
    Kuruvilla, M. Sara
    Liu, Geoffrey
    LUNG CANCER, 2022, 166 : 58 - 62
12345